G. Colțan *, Monica Terteliu *, Cristina Marin *, D. Oțelea *, Mihaela Iosipenco *, F. A. Căruntu *, B. Drăgulănescu **
* Dr. G. Colțan, Dr. Monica Terteliu, Dr. Cristina Marin, Dr. D. Oțelea, Dr. Mihaela losipenco, Dr. F. A. Căruntu – Institutul de Boli lnfecțioase Prof Dr. Matei Balș, București
** Dr. B. Drăgulănescu – Ewopharma
Abstract
Over 110 years, Mantoux test was the only diagnostic used for Mycobacterium tuberculosis screening, at large populational scale. Poor sensitivity and specificity of the test were the main reasons for further immunological and molecular biology researches. Finaly, in 2004, a new tech nological platform was issued: Quantiferon TB Gold. Its sensitivity and specificity, beside a potential introduction as a standard at World wide level with highly reproductible results (over 99.3%} stay as strong positive reasons for a Romanian clinical use, being known that TB prevalence is the highest among EU members or candidates.